(Q36265931)

13 August 2017

1 reference

title

Benefit-risk assessment of levetiracetam in the treatment of partial seizures (English)

1 reference

13 August 2017

1 reference

Bassel Abou-Khalil

1

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

28

1 reference

13 August 2017

10

1 reference

13 August 2017

871-890

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200528100-00004

13 August 2017

0 references

cites work

Landau–Kleffner syndrome responsive to levetiracetam

1 reference

12 December 2020

An open-label study of levetiracetam for the treatment of social anxiety disorder

1 reference

12 December 2020

Efficacy of levetiracetam: a review of three pivotal clinical trials

1 reference

12 December 2020

Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique.

1 reference

12 December 2020

Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia

1 reference

12 December 2020

An open-label pilot study of levetiracetam for essential tremor

1 reference

12 December 2020

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

12 December 2020

Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy

1 reference

12 December 2020

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design

1 reference

12 December 2020

Levetiracetam in the treatment of neuropathic pain: three case studies

1 reference

12 December 2020

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

1 reference

12 December 2020

Pharmacokinetic study of levetiracetam in children

1 reference

12 December 2020

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

1 reference

12 December 2020

Levetiracetam in refractory pediatric epilepsy

1 reference

12 December 2020

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy

1 reference

12 December 2020

Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam

1 reference

12 December 2020

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

12 December 2020

Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials

1 reference

12 December 2020

Tolerability of levetiracetam in elderly patients with CNS disorders

1 reference

12 December 2020

Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study

1 reference

12 December 2020

Psychiatric adverse events during levetiracetam therapy

1 reference

12 December 2020

Limited efficacy of levetiracetam on myoclonus of different etiologies

1 reference

12 December 2020

The effect of levetiracetam on essential tremor

1 reference

12 December 2020

Seizure‐free Days Observed in Randomized Placebo‐controlled Add‐on Trials with Levetiracetam in Partial Epilepsy

1 reference

12 December 2020

Levetiracetam monotherapy for adults with localization-related epilepsy

1 reference

12 December 2020

Efficacy and safety of levetiracetam in pediatric migraine

1 reference

12 December 2020

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

1 reference

12 December 2020

Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication

1 reference

12 December 2020

Amelioration of spinal myoclonus with levetiracetam

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

12 December 2020

Levetiracetam in the treatment of Lennox-Gastaut syndrome

1 reference

12 December 2020

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

12 December 2020

Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease

1 reference

12 December 2020

Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam

1 reference

12 December 2020

Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity

1 reference

12 December 2020

A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data

1 reference

12 December 2020

Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects

1 reference

12 December 2020

Levetiracetam monotherapy for newly diagnosed epilepsy patients.

1 reference

12 December 2020

Levetiracetam psychosis in children with epilepsy

1 reference

12 December 2020

Antimyoclonic effect of levetiracetam

1 reference

12 December 2020

Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid

1 reference

12 December 2020

The pharmacokinetic characteristics of levetiracetam

1 reference

12 December 2020

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.

1 reference

12 December 2020

Levetiracetam in the treatment of rapid cycling bipolar disorder

1 reference

12 December 2020

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women

1 reference

12 December 2020

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

1 reference

12 December 2020

Levetiracetam treatment of idiopathic generalised epilepsy

1 reference

12 December 2020

Levetiracetam use and pregnancy outcome

1 reference

12 December 2020

Levetiracetam concentrations in serum and in breast milk at birth and during lactation

1 reference

12 December 2020

Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.

1 reference

12 December 2020

Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.

1 reference

12 December 2020

Levetiracetam may be more effective for late-onset partial epilepsy

1 reference

12 December 2020

Levetiracetam monotherapy during pregnancy: a case series

1 reference

12 December 2020

Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor

1 reference

12 December 2020

Effect of levetiracetam in refractory childhood epilepsy syndromes

1 reference

12 December 2020

Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices

1 reference

12 December 2020

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial

1 reference

12 December 2020

Levetiracetam for the treatment of essential tremor

1 reference

12 December 2020

Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers

1 reference

12 December 2020

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review

1 reference

12 December 2020

Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam

1 reference

12 December 2020

Levetiracetam in refractory epilepsy: a prospective observational study

1 reference

12 December 2020

Failed surgery for temporal lobe epilepsy: predictors of long-term seizure-free course

1 reference

12 December 2020

Acute psychosis associated with levetiracetam

1 reference

12 December 2020

Early identification of refractory epilepsy

1 reference

12 December 2020

A prospective analysis of the outcome of levetiracetam in clinical practice

1 reference

12 December 2020

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

1 reference

12 December 2020

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial

1 reference

12 December 2020

Pharmacokinetics of levetiracetam

1 reference

12 December 2020

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

1 reference

12 December 2020

Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam.

1 reference

12 December 2020

Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam

1 reference

12 December 2020

Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder

1 reference

12 December 2020

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

12 December 2020

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy

1 reference

12 December 2020

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

1 reference

12 December 2020

Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study

1 reference

12 December 2020

Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.

1 reference

12 December 2020

Suppression of cortical myoclonus by levetiracetam

1 reference

12 December 2020

Levetiracetam in focal epilepsy and hepatic porphyria: a case report

1 reference

12 December 2020

Levetiracetam efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery

1 reference

12 December 2020

Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials

1 reference

12 December 2020

A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus

1 reference

12 December 2020

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

12 December 2020

Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

1 reference

12 December 2020

Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence

1 reference

12 December 2020

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

1 reference

12 December 2020

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

12 December 2020

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

1 reference

12 December 2020

Levetiracetam monotherapy for primary generalised epilepsy

1 reference

12 December 2020

Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents

1 reference

12 December 2020

Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy

1 reference

12 December 2020

In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent

1 reference

12 December 2020

Rapid onset of action of levetiracetam in refractory epilepsy patients

1 reference

12 December 2020

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

1 reference

12 December 2020

Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep

1 reference

12 December 2020

A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy

1 reference

12 December 2020

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

12 December 2020

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

1 reference

12 December 2020

Changing presentation of seizures with aging: clinical and etiological factors

1 reference

12 December 2020

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

1 reference

12 December 2020

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

1 reference

12 December 2020

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin

1 reference

12 December 2020

Long-term experience with levetiracetam

1 reference

12 December 2020

Levetiracetam monotherapy for elderly patients with epilepsy.

1 reference

12 December 2020

Levetiracetam in autistic children: an open-label study

1 reference

12 December 2020

Selective blockade of N-type calcium channels by levetiracetam

1 reference

12 December 2020

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

1 reference

12 December 2020

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

12 December 2020

Levetiracetam for phasic spasticity in multiple sclerosis

1 reference

12 December 2020

Use of levetiracetam in special populations

1 reference

12 December 2020

Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial

1 reference

12 December 2020

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

1 reference

12 December 2020

10.2165/00002018-200528100-00004

Identifiers

DOI

1 reference

PubMed ID

16180937

Dimensions Publication ID

13 August 2017

0 references

1 reference

PubMed ID

16180937